Jacobsen ED, Weinstock DM. Challenges and implications of genomics for T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2018;2018(1):63-68. doi:10.1182/asheducation-2018.1.63
Adam MP, Banka S, Bjornsson HT, et al. Kabuki syndrome: international consensus diagnostic criteria. J Med Genet. 2019;56(2):89-95. doi:10.1136/jmedgenet-2018-105625
Sullivan SE, Liao M, Smith RV, et al. Candidate-based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in Aβ and TAU proteostasis. Hum Mol Genet. 2019;28(5):718-735. doi:10.1093/hmg/ddy376
Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128(10):4441-4453. doi:10.1172/JCI121924
Vazquez F, Sellers WR. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets? Cancer Res. 2021;81(23):5806-5809. doi:10.1158/0008-5472.CAN-21-1784
Zhou JY, Chen L, Zhang B, et al. Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. J Proteome Res. 2017;16(12):4523-4530. doi:10.1021/acs.jproteome.7b00362
Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210. doi:10.1007/s00401-018-1879-y
Kahn JD, Miller PG, Silver AJ, et al. -truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132(11):1095-1105. doi:10.1182/blood-2018-05-850339
Stolte B, Iniguez AB, Dharia NV, et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma. J Exp Med. 2018;215(8):2137-2155. doi:10.1084/jem.20171066
Shankar GM, Kirtane AR, Miller JJ, et al. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018;115(36):E8388-E8394. doi:10.1073/pnas.1805751115